Novo Nordisk consensus picture, shares backed by strong obesity demand

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 07:22.

Novo Nordisk A/S (DK0062498333) continues to attract attention as a leading GLP-1 player. Analyst consensus on the NYSE-listed ADR and Copenhagen shares remains broadly constructive, with the company seen as a core peer to Eli Lilly in the fast-growing obesity segment, according to MarketScreener and other coverage.

How analysts rate Novo Nordisk

Analyst services such as MarketScreener and TipRanks show a majority of Buy or Outperform ratings on Novo Nordisk, with only a handful of Hold recommendations and few outright Sells, reflecting confidence in its long-term GLP-1 franchise. MarketScreener consensus data on Novo Nordisk summarizes the mix of ratings and targets.

The consensus points to continued revenue and earnings growth over the coming years, supported by strong demand for obesity and diabetes treatments and capacity expansion plans in the United States and Europe. Analysts highlight Novo Nordisk's leading position with Wegovy and Ozempic, while also noting competitive pressure from Eli Lilly's Mounjaro and Zepbound in the same therapeutic category.

What market commentary emphasizes today

Recent market commentary from international outlets such as Reuters and the Financial Times has repeatedly underscored Novo Nordisk's role in reshaping expectations for the global pharmaceutical sector via obesity drugs, with GLP-1 treatments now seen as a multi-year growth engine for big pharma. Reuters reporting on obesity drug demand at Nordic pharma groups has described Novo Nordisk and Eli Lilly as central players in this shift.

Commentators note that Novo Nordisk's valuation reflects both strong current profitability and high expectations for the durability of demand, leading to debate about how much future growth is already priced into the shares. Some analysts warn that regulatory or reimbursement changes could add volatility, while still acknowledging the robust underlying prescription trends for GLP-1-based medicines in key markets.

What the company sells today

Novo Nordisk generates most of its revenue from diabetes and obesity medicines, with GLP-1 drugs Ozempic for type 2 diabetes and Wegovy for chronic weight management among its flagship injectable products. The group also markets insulin formulations, rare disease treatments and other hormone therapies.

Where the stock trades today

Novo Nordisk's primary listing is on Nasdaq Copenhagen under the ticker NOVO B, while its ADR trades on the NYSE as NVO; on 2026-06-26, the ADR last closed around 135 USD according to recent market data, reflecting the strong GLP-1 growth story priced into the equity.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.